Barzi, Afsaneh
Lin, Feng http://orcid.org/0000-0001-8520-0420
Song, Jinlin
Lam, Clara
Nie, Xiaoyu
Noman, Ahmed
Kwong, Winghan J.
Funding for this research was provided by:
Daiichi-Sankyo
AstraZeneca
Article History
Accepted: 18 June 2023
First Online: 4 August 2023
Declarations
:
: This study was funded by Daiichi Sankyo, Inc and AstraZeneca.
: Study conceptualization and study design: all authors. Data analysis: Jinlin Song, Xiaoyu Nie, Ahmed Noman. Interpretation of results: all authors. Review and edit the draft manuscript: all authors. Final approval of the manuscript: all authors. All authors have read and approved the final submitted manuscript and agreed to be accountable for the work.
: Not applicable.
: Not applicable.
: Afsaneh Barzi has received consulting fees from Daiichi Sankyo Inc. Feng Lin and Winghan J. Kwong are employees of Daiichi Sankyo, Inc. and hold stock/options. Jinlin Song and Xiaoyu Nie are employees of Analysis Group Inc., which received consulting fees from Daiichi Sankyo, Inc for this study. Ahmed Noman was an employee of Analysis Group Inc. during this study’s conduct. Clara Lam is an employee of AstraZeneca PLC and holds stock/options.
: As the data were de-identified, no institutional review board oversight was required.
: The datasets generated and analyzed during the current study are not publicly available because they were used pursuant to a data use agreement.
: Not applicable.
: Portions of this research were presented in poster form at the NCCN 2021 Virtual Annual Conference held 18–20 March 2021.